PUVA, UVB, psoriasis, and nonmelanoma skin cancer

Studniberg, Howard M.; Weller, Paul

doi:10.1016/0190-9622(93)70283-y

Cited by 116 publications

(46 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…7 It is concerning that although often effective, UV treatment of early-stage MF may create mutations leading to advanced disease, as well as increase risk of secondary skin cancer. 67 Although this is not unique to MF, as secondary malignancies are correlated with other cancer therapies, 68 our data again raise the possibility that UV exposure, including phototherapy, may contribute to MF.…”

Section: Discussionmentioning

confidence: 88%

Whole-genome sequencing reveals oncogenic mutations in mycosis fungoides

McGirt

Jia

Baerenwald

et al. 2015

Blood

204

224

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 88%

Whole-genome sequencing reveals oncogenic mutations in mycosis fungoides

McGirt

Jia

Baerenwald

et al. 2015

Blood

204

224

View full text Add to dashboard Cite

show abstract

“…The development of the TL-01 lamp with a higher therapeutic potential than conventional broadband UV-B sources as well as the increasing awareness of the carcinogenic risk associated with long-term PUVA 6,7 have led to a continuously growing use of narrowband UV-B phototherapy in psoriasis. With regard to the relative therapeutic effectiveness of narrowband UV-B and PUVA, however, only sparse data are available.…”

Section: Commentmentioning

confidence: 99%

“…The assessment of cancer risk resulting from the clinical use of narrowband UV-B is based on retrospective studies on broadband UV-B-treated patients 6,7,27,28 and on mouse studies comparing the carcinogenicity of broadband vs narrowband UV-B. 13,[29][30][31] These data suggest that the cancer risk of equitherapeutic doses of narrowband UV-B is not greater than that of broadband UV-B and substantially lower than that of PUVA.…”

Section: Commentmentioning

confidence: 99%

“…[1][2][3][4] Conversely, treatment with UV-B is much easier to perform, requires less precautions to prevent acute adverse reactions, and seems to harbor a considerably lower carcinogenic potential than PUVA. [5][6][7] Based on these differences, broadband UV-B phototherapy is primarily indicated in patients with mild to moderate psoriasis, whereas for severe forms of PUVA is indicated.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Narrowband UV-B Phototherapy vs Photochemotherapy in the Treatment of Chronic Plaque-Type Psoriasis

Tanew¹,

Radakovic-Fijan²,

Schemper³

et al. 1999

Arch Dermatol

133

122

View full text Add to dashboard Cite

“…Inconsistent results regarding squamous cell carcinoma 25,27 and other nonmelanoma skin cancer 28 rates in UV-B-treated patients have been reported; nevertheless, the calculated increased risk appears to be low. 29 An inherent problem with retrospective studies of skin cancer risk among patients treated with broadband UV-B phototherapy for psoriasis during the 1980s to 1990s is that any small increased incidence of skin cancer must be compared with the incidence in the general population. Increases in melanoma incidence have been reported in retrospective investigations of the Surveillance, Epidemiology, and End Results program of the US National Cancer Institute of 1973 and 1987.…”

Section: Commentmentioning

confidence: 99%

The Safety and Efficacy of the 308-nm Excimer Laser for Pigment Correction of Hypopigmented Scars and Striae Alba

Alexiades-Armenakas

Bernstein

Friedman³

et al. 2004

Arch Dermatol

100

View full text Add to dashboard Cite

To assess the safety and efficacy of the 308-nm excimer laser in pigment correction of hypopigmented scars and striae alba.Design: Institutional review board-approved randomized controlled trial.Setting: Private research center.Patients: Volunteer sample of 31 adult subjects with hypopigmented scars or striae alba distributed on the face, torso, or extremities.Interventions: Lesions were randomized to receive treatment or not, with site-matched normal control areas. Treatments were initiated with a minimal erythema dose minus 50 mJ/cm 2 to affected areas. Subsequent treatments were performed biweekly until 50% to 75% pigment correction, then every 2 weeks thereafter until a maximum of 10 treatments, 75% increase in colorimetric measurements, or 100% visual pigment correction.Main Outcome Measures: Pigment correction by visual and colorimetric assessments compared with untreated control lesions and site-matched normal skin before each treatment and at 1-, 2-, 4-, and 6-month follow-up intervals. Occurrence of erythema, blistering, dyspigmentation, or other adverse effects was monitored. Results:The percentage pigment correction by both assessments increased in direct proportion to the number of treatments. The mean percentage pigment correction by visual assessment relative to control of 61% (95% confidence interval [CI], 55%-67%) for scars and 68% (95% CI, 62%-74%) for striae was achieved after 9 treatments. The mean percentage pigmentation by colorimetric measurements relative to control of 101% (95% CI, 99%-103%) for scars and 102% (95% CI, 99%-104%) for striae was achieved after 9 treatments. Both sets of values gradually declined toward baseline levels during the 6-month follow-up. No blistering or dyspigmentation occurred.Conclusions: Therapy with the 308-nm excimer laser is safe and effective in pigment correction of hypopigmented scars and striae alba. Mean final pigment correction rates relative to control sites of approximately 60% to 70% by visual assessment and 100% by colorimetric analysis were observed after 9 treatments administered biweekly. Maintenance treatment every 1 to 4 months is required to sustain the cosmetic benefit.

show abstract

PUVA, UVB, psoriasis, and nonmelanoma skin cancer

Cited by 116 publications

References 55 publications

Whole-genome sequencing reveals oncogenic mutations in mycosis fungoides

Whole-genome sequencing reveals oncogenic mutations in mycosis fungoides

Narrowband UV-B Phototherapy vs Photochemotherapy in the Treatment of Chronic Plaque-Type Psoriasis

The Safety and Efficacy of the 308-nm Excimer Laser for Pigment Correction of Hypopigmented Scars and Striae Alba

Contact Info

Product

Resources

About